Search

Your search keyword '"Panda, Anshuman"' showing total 162 results
Start Over Author "Panda, Anshuman"
162 results on '"Panda, Anshuman"'

7. Educational Rights of Children with Incarcerated Parents.

Author

Pathak, Puneet and Panda, Anshuman

Subjects
PARENT imprisonment, CHILDREN'S rights, HUMAN rights violations, CHILD development, GOVERNMENT policy
Abstract

The overall development of any child is elevated when they are brought up in a family environment with love, care, and attention. Children with incarcerated parents are often raised in an unstable environment and are subject to various human rights violations; particularly, their right to education is compromised. As per the 27th edition of Prison Statistics India, the number of children living with incarcerated parents in Indian prisons stands at 1,8673. However, this number only accounts for the children allowed to reside in prison with the women prisoners, while the number of children with incarcerated parents living outside prison remains unknown. According to the National Policy for Children, children with incarcerated parents need enhanced care and protection4. This article analyzes the impact of parental incarceration on the educational rights of their children and various legal provisions and government policies on this matter. This article, which is based on a doctrinal research method using secondary data, has found that children with incarcerated parents face varying challenges in accessing their right to education and suggests that legal protection available to children, in general, must be extended to children with incarcerated parents. [ABSTRACT FROM AUTHOR]

Published
2024

9. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Author

Mehnert, Janice M., Panda, Anshuman, Zhong, Hua, Hirshfield, Kim, Damare, Sherri, Lane, Katherine, Sokol, Levi, Stein, Mark N., Rodriguez-Rodriquez, Lorna, Kaufman, Howard L., Ali, Siraj, Ross, Jeffrey S., Pavlick, Dean C., Bhanot, Gyan, White, Eileen P., DiPaola, Robert S., Lovell, Ann, Cheng, Jonathan, and Ganesan, Shridar

Subjects
Gene mutations -- Health aspects, Endometrial cancer -- Genetic aspects -- Development and progression -- Care and treatment, Molecular targeted therapy -- Innovations, DNA polymerases -- Properties, Health care industry
Abstract

Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers. However, anti-PD-1 therapy in some patients provides no benefit and/or results in adverse side effects. The factors that determine whether patients will be drug sensitive or resistant are not fully understood; therefore, genomic assessment of exceptional responders can provide important insight into patient response. Here, we identified a patient with endometrial cancer who had an exceptional response to the anti-PD-1 antibody pembrolizumab. Clinical grade targeted genomic profiling of a pretreatment tumor sample from this individual identified a mutation in DNA polymerase epsilon (POLE) that associated with an ultramutator phenotype. Analysis of The Cancer Genome Atlas (TCGA) revealed that the presence of POLE mutation associates with high mutational burden and elevated expression of several immune checkpoint genes. Together, these data suggest that cancers harboring POLE mutations are good candidates for immune checkpoint inhibitor therapy., Introduction Prolonged and deep responses to antibody therapy directed against the immune checkpoint programmed cell death protein 1 (PD-1) receptor have been demonstrated in multiple types of human cancer (1-7). [...]

Published
2016
Full Text
View/download PDF

10. A Gene Panel for Early Identification of Future Responders to Immune Checkpoint Blockade

Author

Panda, Anshuman, Betigeri, Anil, and Ganesan, Shridar

Subjects
Genetics, Molecular Medicine, Genetics (clinical)
Abstract

Immune checkpoint blockade (ICB), therapies that target the PD-1 pathway, CTLA-4 pathway, and other checkpoint pathways, lead to durable responses in many cancer types. Since only a minority of patients respond to ICB, it may be useful to identify the future responders early in the course of treatment. In this study we evaluated a small (15 genes) biologically motivated panel, consisting of genes involved in immune activation and checkpoint pathways, for early identification of future responders to ICB. The panel passed consistency check, pathological and in-silico validations, and was an excellent predictor (area under ROC curve >0.95) of eventual response to ICB, both CTLA-4 and PD-1 blockade, when applied to metastatic melanoma patients undergoing ICB (i.e., “on-treatment”) in a publicly available dataset. These results suggest that this small biologically motivated panel may be useful for early identification of future responders to ICB.

Published
2022
Full Text
View/download PDF

20. Contrast-enhanced Mammography: How Does It Work?

Author

Sensakovic, William F., primary, Carnahan, Molly B., additional, Czaplicki, Christopher D., additional, Fahrenholtz, Samuel, additional, Panda, Anshuman, additional, Zhou, Yuxiang, additional, Pavlicek, William, additional, and Patel, Bhavika, additional

Published
2021
Full Text
View/download PDF

26. Abstract 4495: DNA demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells

Author

de Cubas, Aguirre A., primary, Dunker, William, additional, Hongo, Rachel, additional, Bhatia, Anuj, additional, Zaninovich, Andrew, additional, Panda, Anshuman, additional, Beckermann, Kathryn E., additional, Bhanot, Gyan, additional, Ganesan, Shridar, additional, Karijolich, John, additional, and Rathmell, W K., additional

Published
2020
Full Text
View/download PDF

27. Abstract 5865: The composition of the human ribosome varies significantly in different normal and malignant tissues

Author

Panda, Anshuman, primary, Yadav, Anupama, additional, Yeerna, Huwate, additional, Singh, Amartya, additional, Biehl, Michael, additional, Lux, Markus, additional, Schulz, Alexander, additional, Klecha, Tyler, additional, Doniach, Sebastian, additional, Khiabanian, Hossein, additional, Ganesan, Shridar, additional, Tamayo, Pablo, additional, and Bhanot, Gyan, additional

Published
2020
Full Text
View/download PDF

28. Tissue- and development-stage–specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples

Author

Panda, Anshuman, primary, Yadav, Anupama, primary, Yeerna, Huwate, primary, Singh, Amartya, primary, Biehl, Michael, primary, Lux, Markus, primary, Schulz, Alexander, primary, Klecha, Tyler, primary, Doniach, Sebastian, primary, Khiabanian, Hossein, primary, Ganesan, Shridar, primary, Tamayo, Pablo, primary, and Bhanot, Gyan, primary

Published
2020
Full Text
View/download PDF

29. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer

Author

de Cubas, Aguirre A., primary, Dunker, William, additional, Zaninovich, Andrew, additional, Hongo, Rachel A., additional, Bhatia, Anuj, additional, Panda, Anshuman, additional, Beckermann, Kathryn E., additional, Bhanot, Gyan, additional, Ganesan, Shridar, additional, Karijolich, John, additional, and Rathmell, W. Kimryn, additional

Published
2020
Full Text
View/download PDF

33. Biomarkers of response to immune checkpoint therapy

Author

Panda, Anshuman

Abstract

Immune checkpoint therapy leads to durable objective response in a subset of patients with metastatic cancer in many different cancer types, but the mechanisms and biomarkers of response to immune checkpoint therapy is not fully understood. Through pan-cancer analysis of the Cancer Genome Atlas, I have so far identified 2 types of predictors of immune activation and checkpoint pathway upregulation in a total of 10 solid cancer types (skin melanoma, lung adenocarcinoma, colon, endometrial, gastric, cervical, ER+ HER2− breast, bladder, clear-cell kidney, and head-neck squamous-cell cancer): (1) hyper-mutation in tumor due to DNA proofreading defect (Chapter 2) or some other etiologies (Chapter 3), and (2) expression of exogenous (Chapter 4) or endogenous (Chapter 5) viral RNA in tumor. I also validated these predictors as biomarkers of response to immune checkpoint therapy in some of the above 10 cancer types where I had access to good quality data, using published datasets of patients treated with immune checkpoint therapy for retrospective validation, and de-identified data of patients treated with immune checkpoint therapy at the Rutgers Cancer Institute of New Jersey and the Vanderbilt Ingram Cancer Center for prospective validation.

Published
2018
Full Text
View/download PDF

34. MRI in acute pancreatitis

Author

Sandrasegaran, Kumaresan, primary, Heller, Matthew T., additional, Panda, Anshuman, additional, Shetty, Anup, additional, and Menias, Christine O., additional

Published
2019
Full Text
View/download PDF

41. SMAD4 is critical in suppression of BRAF-V600Eserrated tumorigenesis

Author

Tong, Kevin, Kothari, Om A., Haro, Katherine S., Panda, Anshuman, Bandari, Manisha M., Carrick, Jillian N., Hur, Joseph J., Zhang, Lanjing, Chan, Chang S., Xing, Jinchuan, Gatza, Michael L., Ganesan, Shridar, and Verzi, Michael P.

Abstract

BRAF-driven colorectal cancer is among the poorest prognosis subtypes of colon cancer. Previous studies suggest that BRAF-mutant serrated cancers frequently exhibit Microsatellite Instability (MSI) and elevated levels of WNT signaling. The loss of tumor-suppressor Smad4in oncogenic BRAF-V600Emouse models promotes rapid serrated tumor development and progression, and SMAD4mutations co-occur in human patient tumors with BRAF-V600Emutations. This study assesses the role of SMAD4 in early-stage serrated tumorigenesis. SMAD4loss promotes microsatellite stable (MSS) serrated tumors in an oncogenic BRAF-V600Econtext, providing a model for MSS serrated cancers. Inactivation of Msh2in these mice accelerated tumor formation, and whole-exome sequencing of both MSS and MSI serrated tumors derived from these mouse models revealed that all serrated tumors developed oncogenic WNT mutations, predominantly in the WNT-effector gene Ctnnb1(β-catenin). Mouse models mimicking the oncogenic β-catenin mutation show that the combination of three oncogenic mutations (Ctnnb1, Braf, and Smad4) are critical to drive rapid serrated dysplasia formation. Re-analysis of human tumor data reveals BRAF-V600Emutations co-occur with oncogenic mutations in both WNT and SMAD4/TGFβ pathways. These findings identify SMAD4 as a critical factor in early-stage serrated cancers and helps broaden the knowledge of this rare but aggressive subset of colorectal cancer.

Published
2021
Full Text
View/download PDF

42. Nanocomposite Hydrogel with Tantalum Microparticles for Rapid Endovascular Hemostasis.

Author

Albadawi, Hassan, Altun, Izzet, Hu, Jingjie, Zhang, Zefu, Panda, Anshuman, Kim, Han‐Jun, Khademhosseini, Ali, and Oklu, Rahmi

Subjects
HYDROGELS, ILIAC artery, HEMOSTASIS, RENAL artery, MAGNETIC resonance imaging, TANTALUM
Abstract

Endovascular embolization to treat vascular hemorrhage involves pushing coil‐shaped metal wires into the artery repeatedly until they are densely packed to slow the blood flow and clot. However, coil embolization is associated with high rebleeding rates, unpredictable economics and, most importantly, they rely on the patient's ability to make a clot. These issues are exacerbated when the patient is anticoagulated or coagulopathic. A novel bioengineered tantalum‐loaded nanocomposite hydrogel for gel embolic material (Ta‐GEM) that can be rapidly delivered using clinical catheters for instant hemostasis regardless of the coagulopathic state is reported. Ta‐GEM formulation is visible by most of the clinically available imaging modalities including ultrasound, computed tomography, magnetic resonance imaging, and fluoroscopy without significant artifact. In addition, Ta‐GEM can be retrieved, allowing temporary vascular occlusion, and it can be used to rescue cases of failed coil embolization. Ta‐GEM occlusion of first‐order arteries such as the renal artery and iliac artery in a swine model is found to be safe and durable; by 28 days, 75% of the injected Ta‐GEM in the arterial lumen is replaced by dense connective tissue. Altogether, this study demonstrates that Ta‐GEM has many advantages over the current technologies and has potential applications in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Sample content of kinesthetic educational training: Reducing scattered X‐ray exposures to interventional physician operators of fluoroscopy.

Author

Pavlicek, William, Sensakovic, William F., Zhou, Yuxiang, Paden, Robert G., Panda, Anshuman, Hines, Justin, Naidu, Sailendra G., and Oklu, Rahmi

Subjects
FLUOROSCOPY, DIGITAL subtraction angiography, X-rays, PERSONAL protective equipment, PHYSICIANS, VASCULAR surgery
Abstract

Content used by Medical Physicists for fluoroscopy safety training to staff is deliverable via several formats, that is, online content or a live audience slide presentations. Here, we share one example of a kinesthetic (live, hands‐on simulation) educational program in use at our facility for some time (~10 years). In this example, the format and content specifically target methods of reducing physician operator exposures from scattered x rays. A kinesthetic format identifies and promotes the adoption of exposure‐reducing behaviors. Key kinesthetic elements of this type of training include: physician hands‐on measurements of radiation levels at locations specific to their standing positions (e.g., primary arterial access points) in the room using handheld exposure rate meters, measurement of exposure rate reduction to physicians provided by using personal protective equipment, that is, wearable aprons, hanging lead drapes, and pull‐down shields. Physician choice of procedure‐specific tableside selectable controls affecting exposure rate from optional fluoroscopy, Cine or digital subtraction angiography (DSA), along with comparative measured contribution to physician exposure is demonstrated. The inverse square exposure rate reduction to physicians when stepping back from the table during DSA is a key observation. Kinesthetic simulations in the rooms used by physicians have been found to provide the highest level of understanding giving rise to adoption of practices that are impactful for physicians. Specific training scripts are in place for physician sub‐specialization in interventional radiology, cardiology, neurosurgery, vascular surgery, and gastroenterology. This training is used for new physician staff while classroom presentations (whose content mimics in room training) are used with staff who have had previously had in room training. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

44. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

Author

Smith, Christof C., primary, Beckermann, Kathryn E., additional, Bortone, Dante S., additional, De Cubas, Aguirre A., additional, Bixby, Lisa M., additional, Lee, Samuel J., additional, Panda, Anshuman, additional, Ganesan, Shridar, additional, Bhanot, Gyan, additional, Wallen, Eric M., additional, Milowsky, Matthew I., additional, Kim, William Y., additional, Rathmell, W. Kimryn, additional, Swanstrom, Ronald, additional, Parker, Joel S., additional, Serody, Jonathan S., additional, Selitsky, Sara R., additional, and Vincent, Benjamin G., additional

Published
2018
Full Text
View/download PDF

45. Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma

Author

Panda, Anshuman, primary, de Cubas, Aguirre A., additional, Stein, Mark, additional, Riedlinger, Gregory, additional, Kra, Joshua, additional, Mayer, Tina, additional, Smith, Christof C., additional, Vincent, Benjamin G., additional, Serody, Jonathan S., additional, Beckermann, Kathryn E., additional, Ganesan, Shridar, additional, Bhanot, Gyan, additional, and Rathmell, W. Kimryn, additional

Published
2018
Full Text
View/download PDF

48. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

Author

Panda, Anshuman, primary, Mehnert, Janice M, additional, Hirshfield, Kim M, additional, Riedlinger, Greg, additional, Damare, Sherri, additional, Saunders, Tracie, additional, Kane, Michael, additional, Sokol, Levi, additional, Stein, Mark N, additional, Poplin, Elizabeth, additional, Rodriguez-Rodriguez, Lorna, additional, Silk, Ann W, additional, Aisner, Joseph, additional, Chan, Nancy, additional, Malhotra, Jyoti, additional, Frankel, Melissa, additional, Kaufman, Howard L, additional, Ali, Siraj, additional, Ross, Jeffrey S, additional, White, Eileen P, additional, Bhanot, Gyan, additional, and Ganesan, Shridar, additional

Published
2017
Full Text
View/download PDF

49. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors

Author

Panda, Anshuman, primary, Betigeri, Anil, additional, Subramanian, Kalyanasundaram, additional, Ross, Jeffrey S., additional, Pavlick, Dean C., additional, Ali, Siraj, additional, Markowski, Paul, additional, Silk, Ann, additional, Kaufman, Howard L., additional, Lattime, Edmund, additional, Mehnert, Janice M., additional, Sullivan, Ryan, additional, Lovly, Christine M., additional, Sosman, Jeffrey, additional, Johnson, Douglas B., additional, Bhanot, Gyan, additional, and Ganesan, Shridar, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results